Lumos Diagnostics Holdings Limited
LDX.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$94.48M
Close$
Share Statistics
| Market cap | $94.48 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 0.54 |
| Outstanding Shares | 944,389,135 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -10.75 |
|---|---|
| PEG | 10.93 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$10.06 M
Average shareholder expectationNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$13.19 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lumos Diagnostics Holdings Limited
29 employees
CEO: Douglas Ward Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-...